KR102411799B1 - 면역자극성 올리고뉴클레오티드를 포함하는 배합물 - Google Patents

면역자극성 올리고뉴클레오티드를 포함하는 배합물 Download PDF

Info

Publication number
KR102411799B1
KR102411799B1 KR1020187006249A KR20187006249A KR102411799B1 KR 102411799 B1 KR102411799 B1 KR 102411799B1 KR 1020187006249 A KR1020187006249 A KR 1020187006249A KR 20187006249 A KR20187006249 A KR 20187006249A KR 102411799 B1 KR102411799 B1 KR 102411799B1
Authority
KR
South Korea
Prior art keywords
seq
days
dna
coding sequence
linear
Prior art date
Application number
KR1020187006249A
Other languages
English (en)
Korean (ko)
Other versions
KR20180050309A (ko
Inventor
마티아스 슈로프
마누엘 슈미트
커스틴 캡
알프레도 줄로
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20180050309A publication Critical patent/KR20180050309A/ko
Application granted granted Critical
Publication of KR102411799B1 publication Critical patent/KR102411799B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020187006249A 2015-09-09 2016-09-09 면역자극성 올리고뉴클레오티드를 포함하는 배합물 KR102411799B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU92821A LU92821B1 (en) 2015-09-09 2015-09-09 Combination comprising immunostimulatory oligonucleotides
LU92821 2015-09-09
PCT/EP2016/071314 WO2017042336A1 (en) 2015-09-09 2016-09-09 Combination comprising immunostimulatory oligonucleotides

Publications (2)

Publication Number Publication Date
KR20180050309A KR20180050309A (ko) 2018-05-14
KR102411799B1 true KR102411799B1 (ko) 2022-06-23

Family

ID=54251700

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187006249A KR102411799B1 (ko) 2015-09-09 2016-09-09 면역자극성 올리고뉴클레오티드를 포함하는 배합물

Country Status (19)

Country Link
US (3) US10487333B2 (ja)
EP (1) EP3347468B1 (ja)
JP (3) JP2018530530A (ja)
KR (1) KR102411799B1 (ja)
CN (1) CN108138179B (ja)
AU (1) AU2016319214B2 (ja)
BR (1) BR112018004246A2 (ja)
CA (1) CA2997319C (ja)
ES (1) ES2905891T3 (ja)
HK (1) HK1257273A1 (ja)
IL (1) IL257921B (ja)
LU (1) LU92821B1 (ja)
MX (1) MX2018002665A (ja)
PL (1) PL3347468T3 (ja)
PT (1) PT3347468T (ja)
RU (1) RU2766693C2 (ja)
SI (1) SI3347468T1 (ja)
WO (1) WO2017042336A1 (ja)
ZA (1) ZA201801001B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014292926B2 (en) 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
AU2016332725A1 (en) 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
EP3392345A1 (en) 2017-04-22 2018-10-24 Mologen AG Biomarker for small cell lung cancer therapy
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
JP2020531555A (ja) * 2017-08-31 2020-11-05 モロゲン・アーゲー 腫瘍微小環境のモジュレーションのためのｔｌｒ−９アゴニスト
TW202011959A (zh) 2018-04-14 2020-04-01 美商戴納瓦克斯技術公司 用於治療癌症之包括CpG-C 型寡核苷酸及組蛋白去乙醯酶抑制劑之組合
CN112007149A (zh) * 2019-05-29 2020-12-01 思格(苏州)生物科技有限公司 一种新型复合免疫佐剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131495A2 (de) 2006-05-11 2007-11-22 Mologen Ag Multimer zur immunstimulation
WO2015124614A1 (en) 2014-02-18 2015-08-27 Mologen Ag Covalently closed non-coding immunomodulatory dna construct

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191115253A (en) 1911-06-30 1912-06-20 Adolph Schneider Improvements in Bottle-filling Machines.
US2382696A (en) 1939-04-01 1945-08-14 Milleville Marie Joseph Mau De Method and apparatus for filling containers
GB684057A (en) 1949-11-30 1952-12-10 Stockholms Bryggerier Ab Machine of the rotatory table type for the treatment of bottles and the like containers
US2699718A (en) 1952-04-10 1955-01-18 Francis X Wright Filling apparatus with beverage preparation mechanism
FR1418965A (fr) 1964-10-14 1965-11-26 Chelle Ets Tireuse de liquides à double utilisation
AU554222B2 (en) 1981-10-13 1986-08-14 Toyo Garasu K.K. Inspecting glass containers
ES2099718T3 (es) 1990-07-02 1997-06-01 Hoechst Ag Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales.
DE69431669T2 (de) 1993-09-02 2003-10-23 Ribozyme Pharm Inc Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FR2732971B1 (fr) 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
HUP0001107A3 (en) 1996-10-16 2003-01-28 Icn Pharmaceuticals Inc Costa Monocyclic l-nucleosides, analogs and pharmaceutical compositions thereof
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6192481B1 (en) 1998-08-18 2001-02-20 International Business Machines Corporation Structure and method for power sequencing of disk drives in a computer system
CA2371994C (en) 1999-02-26 2010-09-28 Guido Grandi Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6737066B1 (en) 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
DE60023300T2 (de) 1999-06-29 2006-07-06 Glaxosmithkline Biologicals S.A. Verwendung von cpg als adjuvans für hivimpstoff
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
AU1656601A (en) 1999-11-12 2001-06-12 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
AU2001294750C1 (en) 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
EP1355661A2 (de) 2001-01-31 2003-10-29 Mologen Forschungs-, Entwicklungs- und Vertriebs GmbH Tumorvakzine
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
AU2002349278A1 (en) 2001-10-02 2003-04-22 Mologen Ag Dna-expression construct for treatment of infections with leishmaniasis
CN1310676C (zh) 2001-10-02 2007-04-18 莫洛根股份公司 提高免疫应答的方法
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
JP2003204793A (ja) 2002-01-15 2003-07-22 Takeda Chem Ind Ltd ウイルス性疾患の予防または治療剤
DE10211558A1 (de) 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003287332A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7501503B2 (en) 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
WO2004084940A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
PT1631672E (pt) 2003-06-10 2007-01-31 Mologen Ag Vector de expressão circular destinado a aplicações na terapia genetica
SG123799A1 (en) 2003-10-30 2006-07-26 Coley Pharm Gmbh C-class oligonucleotide analogs with enchanced immunostimulatory potency
EP1691817A2 (en) 2003-12-02 2006-08-23 Corgentech, Inc. NF-kB OLIGONUCLEOTIDE DECOY MOLECULES
RU2354694C2 (ru) 2003-12-30 2009-05-10 Мологен Аг Аллогенное противоопухолевое терапевтическое средство
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
US20090004703A1 (en) 2004-05-28 2009-01-01 Mologen Ag Method for the Production of Suitable Dna Constructs for Specific Inhibition of Gene Expression by Rna Interference
EP2901856B1 (en) 2004-06-15 2017-08-09 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
WO2006091591A1 (en) 2005-02-22 2006-08-31 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
WO2006116458A2 (en) 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhances immunostimulatory activity
US20090169472A1 (en) 2005-10-12 2009-07-02 Cancer Research Technology Ltd. Methods and compositions for treating immune disorders
US8357665B2 (en) 2005-10-12 2013-01-22 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
BRPI0618473A2 (pt) 2005-11-11 2011-08-30 Pfizer combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador
DK1951870T3 (da) 2005-11-25 2013-07-29 Mologen Ag DNA-konstrukter til specifik inhibering af genekspression ved RNA-interferens
CA2630738C (en) 2005-11-25 2013-09-03 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
RU2008135318A (ru) 2006-02-01 2010-03-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии неопластических или инфекционных заболеваний
EP2032144A4 (en) 2006-06-13 2011-05-04 Bayhill Therapeutics Inc METHODS AND COMPOSITIONS BASED ON NUCLEIC ACID MODULATORS OF THE IMMUNE SYSTEM FOR THE PREVENTION AND TREATMENT OF DISEASE
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2008262478C1 (en) 2007-05-29 2014-06-19 Aldevron, L.L.C. Vectors and methods for genetic immunization
US8080634B2 (en) 2007-07-27 2011-12-20 Immatics Biotechnologies Gmbh Immunogenic epitope for immunotherapy
WO2009035554A2 (en) 2007-09-07 2009-03-19 University Of Florida Research Foundation, Inc. Superior structure stability and selectivity of hairpin nucleic acid probes with an l-dna stem
RU2010112771A (ru) 2007-10-09 2011-11-20 Коули Фармасьютикал ГмбХ (DE) Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
EP2058397A1 (de) 2007-11-07 2009-05-13 Mologen AG Multimeres Assemblat zur Immunstimulation
WO2009069447A1 (ja) 2007-11-28 2009-06-04 Toray Industries, Inc. インフルエンザワクチン用のアジュバント及びインフルエンザワクチン
JP5359883B2 (ja) 2007-11-28 2013-12-04 東レ株式会社 肝炎の治療剤又は予防剤
WO2010039137A1 (en) 2008-10-02 2010-04-08 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
EP2246433A1 (de) 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
KR20130063493A (ko) 2010-03-26 2013-06-14 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｉｖ 백신
GB201021873D0 (en) 2010-12-23 2011-02-02 Mologen Ag DNA expression construct
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
JP5761707B2 (ja) 2011-02-02 2015-08-12 国立研究開発法人産業技術総合研究所 高効率細胞融合法
EP2744830A4 (en) * 2012-06-21 2015-06-17 Compugen Ltd ANTI-LSR ANTIBODIES AND THEIR USES FOR THE TREATMENT OF CANCER
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
EP3392345A1 (en) 2017-04-22 2018-10-24 Mologen AG Biomarker for small cell lung cancer therapy
JP2020531555A (ja) 2017-08-31 2020-11-05 モロゲン・アーゲー 腫瘍微小環境のモジュレーションのためのｔｌｒ−９アゴニスト

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131495A2 (de) 2006-05-11 2007-11-22 Mologen Ag Multimer zur immunstimulation
WO2015124614A1 (en) 2014-02-18 2015-08-27 Mologen Ag Covalently closed non-coding immunomodulatory dna construct

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Acta Universitatis Upsaliensis 506(1-84) (2009.12.15.)
Cancer Research 73(23):6900-6912 (2013.12.01)
Cancer Research 74(4):1045-1055 (2014.02.15)
Immunology letters 127(1):60-67 (2009.12.02.)

Also Published As

Publication number Publication date
SI3347468T1 (sl) 2022-02-28
CN108138179B (zh) 2022-05-13
IL257921A (en) 2018-05-31
ES2905891T3 (es) 2022-04-12
AU2016319214A1 (en) 2018-03-15
AU2016319214B2 (en) 2021-12-23
RU2766693C2 (ru) 2022-03-15
US10604760B2 (en) 2020-03-31
RU2018108353A (ru) 2019-10-09
KR20180050309A (ko) 2018-05-14
US20210010003A1 (en) 2021-01-14
RU2018108353A3 (ja) 2020-02-28
PL3347468T3 (pl) 2022-03-21
CA2997319A1 (en) 2017-03-16
US10487333B2 (en) 2019-11-26
JP2022060368A (ja) 2022-04-14
IL257921B (en) 2022-09-01
US11578331B2 (en) 2023-02-14
JP2018530530A (ja) 2018-10-18
ZA201801001B (en) 2019-05-29
LU92821B1 (en) 2017-03-20
CN108138179A (zh) 2018-06-08
JP2021059566A (ja) 2021-04-15
BR112018004246A2 (pt) 2018-09-25
MX2018002665A (es) 2018-06-13
US20180251767A1 (en) 2018-09-06
EP3347468A1 (en) 2018-07-18
US20190316134A1 (en) 2019-10-17
PT3347468T (pt) 2022-02-18
JP7436535B2 (ja) 2024-02-21
WO2017042336A1 (en) 2017-03-16
EP3347468B1 (en) 2021-12-15
CA2997319C (en) 2023-01-10
HK1257273A1 (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
KR102411799B1 (ko) 면역자극성 올리고뉴클레오티드를 포함하는 배합물
JP6885867B2 (ja) 組合せ腫瘍免疫療法
Buchta et al. Toll-like receptors and B cells: functions and mechanisms
Krieg Therapeutic potential of Toll-like receptor 9 activation
Murad et al. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer
KR101985382B1 (ko) 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(ｉｒｏ) 화합물
Kornbluth et al. Immunostimulatory combinations: designing the next generation of vaccine adjuvants
WO2016123573A1 (en) Peritumoral and intratumoral materials for cancer therapy
JP6067893B2 (ja) 非コード免疫調節性共有結合閉鎖ｄｎａ構築物
CA2624755A1 (en) Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
Lipford et al. Poly‐guanosine motifs costimulate antigen‐reactive CD8 T cells while bacterial CpG‐DNA affect T‐cell activation via antigen‐presenting cell‐derived cytokines
Wang et al. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics
KR20180053664A (ko) Hiv 치료 방법
WO2019160866A2 (en) Compositions and methods for tumor immunotherapy
Saha et al. Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell‐based immunotherapy of colon cancer in CEA/HLA‐A2 transgenic mice
CA3214965A1 (en) Targeting multiple t cell types using spherical nucleic acid vaccine architecture
Kandimalla et al. Modulation of endosomal Toll-like receptor-mediated immune responses by synthetic oligonucleotides
Soldevilla et al. Aptamers as a Promising Therapeutic Tool for Cancer Immunotherapy
Speiser et al. Stimulation of Toll‐Like Receptor 9 for Enhancing Vaccination

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right